J Hum Hypertens. 1994 Dec;8(12):907-10.
Doxazosin, a once daily alpha-blocking drug has been demonstrated to reduce both BP and hyperlipidaemia, related risk factors for premature vascular disease. This study was designed to see if a low fat diet altered the favourable effect of doxazosin on blood lipids in adults with mild to moderate hypertension and mild to moderate hypercholesterolaemia (5.6-8.0 mmol/l). Following a six week period on a low fat diet, patients were randomly allocated to additional doxazosin (2-8 mg/day) or enalapril (5-20 mg/day) treatment for a further 10 weeks. Forty-four of 55 subjects completed the study. A low fat diet reduced mean body weight by 2 kg without significantly altering blood lipids (total and HDL cholesterol, triglycerides). Doxazosin (4.5 +/- 2.9 mg/day) and enalapril (12.5 +/- 6.5 mg/day) produced a comparable lowering of sitting and standing BP at all visits and also produced similar 24h BP control. The expected increase in HDL cholesterol concentration previously noted in this patient population in association with doxazosin treatment was not detected suggesting that the low cholesterol-high carbohydrate diet, at least acutely, attenuates this potentially beneficial effect on plasma lipids. In summary, doxazosin has a comparable tolerability and BP lowering ability to enalapril. However, its ability to increase HDL cholesterol may be reduced in patients on low fat diets.
多沙唑嗪是一种每日服用一次的α受体阻滞剂,已被证明可降低血压和高脂血症,这些都是血管过早病变的相关危险因素。本研究旨在观察低脂饮食是否会改变多沙唑嗪对轻度至中度高血压和轻度至中度高胆固醇血症(5.6 - 8.0 mmol/l)成人血脂的有益作用。在进行六周的低脂饮食后,患者被随机分配接受额外的多沙唑嗪(2 - 8毫克/天)或依那普利(5 - 20毫克/天)治疗,为期10周。55名受试者中有44名完成了研究。低脂饮食使平均体重减轻了2千克,但未显著改变血脂(总胆固醇和高密度脂蛋白胆固醇、甘油三酯)。多沙唑嗪(4.5±2.9毫克/天)和依那普利(12.5±6.5毫克/天)在所有访视时均使坐位和站位血压有类似程度的降低,并且24小时血压控制情况也相似。此前在该患者群体中观察到的与多沙唑嗪治疗相关的高密度脂蛋白胆固醇浓度预期升高未被检测到,这表明低胆固醇 - 高碳水化合物饮食至少在短期内会减弱其对血脂的潜在有益作用。总之,多沙唑嗪与依那普利具有相当的耐受性和降压能力。然而,在低脂饮食的患者中,其升高高密度脂蛋白胆固醇的能力可能会降低。